New funding will support the phase 2 expansion trial of THEO-260 More: Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study Source: News
read moreThe primary growth drivers in Bayer’s pharma sector—Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. But that won’t lead to growth of Bayer’s pharma business overall this year as
read moreNot long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its Wegovy pill, another of the Danish drugmaker’s GLP-1 ads is in the regulator’s crosshairs. More: Novo lands another
read morePfizer CEO Albert Bourla, Ph.D., has weighed in with sharp criticism of the FDA’s Vinay Prasad, M.D., and his performance as the chief of the Center for Biologics Evaluation and Research, which regulates vaccines in the U.S. More: Pfizer CEO
read more
DementAI prototype developed by Katalyze Data seeks to ease pressure on clinical teams More: AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays Source: News
read more
Company targets new approach to treating rheumatoid arthritis and systemic sclerosis More: Quell launches chill phase 1/2 trial for novel cartreg therapy Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals